Register Login

RIGEL PHARMACEUTICALS INC (RIGL)

(90% Positive) RIGEL PHARMACEUTICALS INC (RIGL) Announces Enrollment Update for results Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 5, 2026, 8:17 p.m.

    📋 RIGEL PHARMACEUTICALS INC (RIGL) - Clinical Trial Update

    Filing Date: 2026-05-05

    Accepted: 2026-05-05 16:08:21

    Event Type: Clinical Trial Update

    Event Details:

    RIGEL PHARMACEUTICALS INC (RIGL) Announces Clinical Trial Update RIGEL PHARMACEUTICALS INC (RIGL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results
    • Clinical Stage: Phase 2
    • Collaboration: TAVALISSE®
      • anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of TAVALISSE, GAVRETO, and REZLIDHIA; risks that the FDA, European Medicines Agency, PMDA or other regulatory authorities may make adverse decisions regarding TAVALISSE, GAVRETO, REZLIDHIA or R289; operational, regulatory or other risks that can affect the timing of enrollment and data availability for R289 clinical development; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that TAVALISSE, GAVRETO, REZLIDHIA or R289 may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop or market Rigel’s product candidates; market competition; product demand variability pricing/reimbursement dynamics unanticipated business needs and other developments, including potential partnering, licensing or other collaboration arrangements, which could impact Rigel’s funding needs or other internal resource demands, as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025

    🔬 Clinical Development Pipeline (RIGEL PHARMACEUTICALS INC):

    Product Type Development Stage Therapeutic Area Source
    Fostamatinib Disodium tablet 150 mg Other Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    Fostamatinib Disodium tablet 100 mg Other Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    Placebo Other Phase PHASE1 Keratoconjunctivitis Sicca ClinicalTrials.gov
    R348 Ophthalmic Solution, 1.0% Other Phase PHASE1 Keratoconjunctivitis Sicca ClinicalTrials.gov
    R348 Ophthalmic Solution, 0.5% Other Phase PHASE1 Keratoconjunctivitis Sicca ClinicalTrials.gov
    R348 Ophthalmic Solution, 0.2% Other Phase PHASE1 Keratoconjunctivitis Sicca ClinicalTrials.gov
    R932333 Other Phase PHASE2 Lupus Erythematosus, Discoid ClinicalTrials.gov
    R940343 2mg Other Phase PHASE2 Asthma ClinicalTrials.gov
    R940343 1mg Other Phase PHASE2 Asthma ClinicalTrials.gov
    Placebo Ophthalmic Solution Other Phase PHASE2 Chronic Graft-versus-host Disease ClinicalTrials.gov
    Fostamatinib disodium 150 mg Other Preclinical Immune Thrombocytopenic Purpura ClinicalTrials.gov
    Fostamatinib disodium 100 mg Other Preclinical Immune Thrombocytopenic Purpura ClinicalTrials.gov
    Fostamatinib Disodium Other Phase PHASE3 Immune Thrombocytopenic Purpura ClinicalTrials.gov
    Fostamatinib 100 mg Other Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    Fostamatinib 150 mg Other Phase PHASE2 IGA Nephropathy ClinicalTrials.gov
    Fostamatinib 150 mg bid Other Phase PHASE2 Warm Antibody Autoimmune Hemolytic Anemia ClinicalTrials.gov
    Fostamatinib Other Phase PHASE2 Hidradenitis Suppurativa ClinicalTrials.gov
    Ruxolitinib Other Phase PHASE2 Myelofibrosis ClinicalTrials.gov
    Fostamatinib 200 mg bid and Paclitaxel Other Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    Fostamatinib 150 mg bid and Paclitaxel Other Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    Fostamatinib 100 mg bid and Paclitaxel Other Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    Olutasidenib + TMZ Other Phase PHASE2 High Grade Glioma ClinicalTrials.gov
    R906289 Monosodium (R289 Na) Other Phase PHASE1 Low Risk Myelodysplastic Syndromes ClinicalTrials.gov
    Olutasidenib Investigational Agent Administration Other Phase PHASE1 Acute Myeloid Leukemia ClinicalTrials.gov
    Olutasidenib Other Phase PHASE2 Myelodysplastic Syndromes ClinicalTrials.gov
    CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates Other Phase PHASE4 AML (Acute Myeloid Leukemia) ClinicalTrials.gov
    Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) Drug Phase PHASE1 Pancreatic Ductal Adenocarcinoma (PDAC) ClinicalTrials.gov
    Decitabine/cedazuridine Other Phase PHASE1 Mutant IDH1 Inhibitor Olutasidenib ClinicalTrials.gov
    Decitabine Other Phase PHASE1 Mutant IDH1 Inhibitor Olutasidenib ClinicalTrials.gov
    Venetoclax Other Phase PHASE1 Mutant IDH1 Inhibitor Olutasidenib ClinicalTrials.gov
    Cytarabine Other Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Gilteritinib Other Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Cladribine (CLAD) Other Phase PHASE2 Targeted Therapy ClinicalTrials.gov
    Azacitidine Other Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    ORE1001 DRUG Phase PHASE1 Mild to Moderate Ulcerative Colitis ClinicalTrials.gov
    JNJ-32729463 (Open-Label) DRUG Phase PHASE2 Community-Acquired Bacterial Pneumonia (CABP) ClinicalTrials.gov
    moxifloxacin DRUG Phase PHASE2 Community-Acquired Bacterial Pneumonia (CABP) ClinicalTrials.gov
    JNJ-32729463 DRUG Phase PHASE2 Community-Acquired Bacterial Pneumonia (CABP) ClinicalTrials.gov
    RP-G28 or placebo DRUG Phase PHASE2 Lactose Intolerance ClinicalTrials.gov
    linezolid placebo DRUG Phase PHASE2 Complicated Skin and Skin Structure Infections ClinicalTrials.gov
    JNJ-32729463 placebo DRUG Phase PHASE2 Complicated Skin and Skin Structure Infections ClinicalTrials.gov
    linezolid DRUG Phase PHASE2 Complicated Skin and Skin Structure Infections ClinicalTrials.gov
    Atorvastatin DRUG Phase PHASE2 Myalgia ClinicalTrials.gov
    PPD10558 DRUG Phase PHASE2 Myalgia ClinicalTrials.gov
    RP-G28 DRUG Phase PHASE2 Lactose Intolerance ClinicalTrials.gov
    Eluxadoline DRUG Phase PHASE3 Irritable Bowel Syndrome ClinicalTrials.gov
    [Tc-99m]-RPI-T-087 Injection DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Placebos DRUG Phase PHASE3 Lactose Intolerance ClinicalTrials.gov
    Vehicle ophthalmic solution OTHER Phase PHASE3 Blepharoptosis ClinicalTrials.gov
    RVL-1201 DRUG Phase PHASE3 Blepharoptosis ClinicalTrials.gov
    RVL-1201 Vehicle Placebo DRUG Phase PHASE1 Blepharoptosis ClinicalTrials.gov
    arbaclofen DRUG Phase PHASE3 Multiple Sclerosis ClinicalTrials.gov
    baclofen DRUG Phase PHASE3 Spasticity ClinicalTrials.gov
    Placebo for arbaclofen ER tablets DRUG Phase PHASE3 Multiple Sclerosis ClinicalTrials.gov
    arbaclofen ER Tablets DRUG Phase PHASE3 Multiple Sclerosis ClinicalTrials.gov
    RVP-001 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Standard of care OTHER Phase PHASE1 Coronavirus ClinicalTrials.gov
    Azacitidine (AZA) DRUG Phase PHASE2 IDH1 Mutation ClinicalTrials.gov
    Fostamatinib Disodium (R935788) DRUG Phase PHASE2 Systemic Lupus Erythematosus ClinicalTrials.gov
    Fostamatinib Disodium / R935788 DRUG Phase PHASE2 Purpura, Thrombocytopenic, Idiopathic ClinicalTrials.gov
    R788 DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    Beclomethasone dipropionate DRUG Phase PHASE2 Rhinitis, Allergic, Seasonal ClinicalTrials.gov
    R926112 DRUG Phase PHASE2 Rhinitis, Allergic, Seasonal ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: RIGEL PHARMACEUTICALS INC
    • Ticker Symbol: RIGL

Search

News categories